HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Robert J. Downey Bernard Park Valerie Rusch Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Downey, R. J. Articles by Rusch, V. Search for Related Content PubMed PubMed Citation Articles by Downey, R. J. Articles by Rusch, V. Related Collections Related Article

J Thorac Cardiovasc Surg 2007;133:1419-1427
© 2007 The American Association for Thoracic Surgery

General Thoracic Surgery

Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non–small cell lung cancer

^a Thoracic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
^b Division of Nuclear Medicine, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY
^c Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.

Read at the Eighty-sixth Annual Meeting of The American Association for Thoracic Surgery, Philadelphia, Pa, April 29-May 3, 2006.

Received for publication June 29, 2006; revisions received December 6, 2006; accepted for publication January 8, 2007.

^_* Address for reprints: Robert J. Downey, MD, Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021. (Email: downeyr{at}mskcc.org).

Objectives: Positron emission tomographic maximal standardized uptake value has been shown to predict survival after resection of non–small cell lung cancer. The relative prognostic benefit of maximal standardized uptake value with respect to other clinical/pathologic variables has not been defined.

Methods: We reviewed patients who had positron emission tomographic imaging and an R0 resection for non–small cell lung cancer between January 1, 2000, and December 31, 2004, without induction or adjuvant therapy. The associations between overall survival, histology, pathologic TNM stage, pathologic tumor diameter, and standardized uptake value were tested.

Results: Four hundred eighty-seven patients met the study criteria. Median follow-up was 25.8 months. By using the median values for tumor size (2.5 cm) and standardized uptake value (5.3), standardized uptake value was an independent predictor of survival (P = .03), adjusting for tumor size (P = .02) and histology (P < .01). The optimal standardized uptake value for stratification was identified as 4.4, and this value was identified as an independent predictor of survival (P = .03) after adjusting for clinical TNM stage. Standardized uptake value was not an independent predictor of survival (P = .09), adjusting for pathologic TNM stage (stage IA vs IB vs stage II–IV, P < .01).

Conclusions: Standardized uptake value does not add to the prognostic significance of pathologic TNM stage. Standardized uptake value was an independent prognostic factor from clinical TNM stage.

Related Article

Discussion
J. Thorac. Cardiovasc. Surg. 2007 133: 1425-1427. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				J. L. Lopez Guerra, G. Gladish, R. Komaki, D. Gomez, Y. Zhuang, and Z. Liao Large Decreases in Standardized Uptake Values After Definitive Radiation Are Associated with Better Survival of Patients with Locally Advanced Non-Small Cell Lung Cancer J. Nucl. Med., February 1, 2012; 53(2): 225 - 233. [Abstract] [Full Text] [PDF]

				T.-W. Huang, C.-M. Hsieh, H. Chang, Y.-L. Cheng, C. Tzao, W.-S. Huang, and S.-C. Lee Standard uptake value of positron emission tomography in clinical stage I lung cancer: clinical application and pathological correlation Eur J Cardiothorac Surg, December 21, 2011; (2011) ezr113v1. [Abstract] [Full Text] [PDF]

				R. Boellaard Need for Standardization of 18F-FDG PET/CT for Treatment Response Assessments J. Nucl. Med., December 1, 2011; 52(Supplement_2): 93S - 100S. [Abstract] [Full Text] [PDF]

				S. Barnett, J.-M. Baste, K. Murugappan, C. Tog, S. Berlangieri, A. Scott, S. Seevanayagam, and S. Knight Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: the impact of 2-18F-fluoro-2-deoxy-D-glucose positron emission tomogram mediastinal staging Eur J Cardiothorac Surg, January 1, 2011; 39(1): 96 - 101. [Abstract] [Full Text] [PDF]

				V. S. Nair, P. G. Barnett, L. Ananth, M. K. Gould, and for the Veterans Affairs Solitary Nodule Accuracy PET Scan 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients With Resected Clinical Stage IA Non-small Cell Lung Cancer Chest, May 1, 2010; 137(5): 1150 - 1156. [Abstract] [Full Text] [PDF]

				N. Kanauchi, H. Oizumi, T. Honma, H. Kato, M. Endo, J. Suzuki, K. Fukaya, and M. Sadahiro Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer Eur J Cardiothorac Surg, April 1, 2009; 35(4): 706 - 711. [Abstract] [Full Text] [PDF]

				A. J. Poncelet, M. Lonneux, and F.-X. Hanin Reply to Chong Eur J Cardiothorac Surg, October 1, 2008; 34(4): 932 - 933. [Full Text] [PDF]

				C. F. Chong Re: Prognostic value of FDG uptake in early stage non-small cell lung cancer Eur J Cardiothorac Surg, October 1, 2008; 34(4): 932 - 932. [Full Text] [PDF]